Navigation Links
Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching Commercialization
Date:9/5/2013

Rockville, Maryland (PRWEB) September 05, 2013

Fisher BioServices Inc., a leading provider of biorepository/biobanking and ultra cold chain logistics services, announced that Dan O’Donnell, Associate Director of Cell Therapy Logistics, will speak at three upcoming industry conferences. Mr. O’Donnell, who is widely known for his expertise on ultra cold chain distribution and regulatory compliance in transporting biologics and cryogenically frozen cell-based therapeutics, has been invited to present at the International Society for Cellular Therapy (ISCT) North America Regional Meeting in Philadelphia, Pennsylvania (September 8–11), the Stem Cell & Regenerative Medicine USA Congress in Cambridge, Massachusetts (September 30–October 1), and the ColdChainIQ 11th Annual GDP & Temperature Management Logistics Global Forum in Chicago, Illinois (September 30–October 4).

Mr. O’Donnell will share his expertise on the challenges of moving high value biologics at ultra cold temperatures from the manufacturer to the patient bedside—in clinical trials as well as in the commercial marketplace. This will include an overview of how product packaging and clinical trial design can complicate logistics, add expense, and limit the number of clinical sites available for conducting phase II and phase III clinical trials. He will use a case study format to illustrate the technical challenges of meeting FDA requirements while moving products around the world at cryogenic temperatures, and share his experience with both autologous and allogeneic cell-based therapies.

Industry professionals who’d like to learn more about the latest end-to-end cell therapy solutions from Fisher BioServices can register for Mr. O’Donnell’s webinar - “Ultra Cold Chain & Logistical Challenges in Cell Therapy Clinical and Commercial Development” on October 10th, 2013. As Fisher BioServices’ Associate Director of Cell Therapy Logistics, Mr. O’Donnell has worked with numerous clients and assisted them in designing and implementing their ultra cold chain strategies which include packaging, qualified shipping systems, and patient delivery mechanisms that are cost-effective and align with patient safety needs and FDA requirements. He brings extensive experience and insight to the process of commercialization and distribution of biological therapeutics. Mr. O’Donnell’s webinar will include his insights and address some of the topics in his recent eBook, Commercially Successful Cell Therapies: Navigating the Ultra Cold Chain Distribution Minefield. Attendees will have the opportunity to ask questions. Mr. O’Donnell’s eBook is available at blog.fisherbioservices.com. To learn more or register for the webinar, go to http://connect.fisherbioservices.com/webinar/cell_therapy_webinar_clinical_trials_commercialization

About Fisher BioServices

Fisher BioServices has 28 years of experience in biorepository/biobanking services, cold chain logistics, and related support services for health-related research. The company manages high value biological specimens, cell-based therapeutics, vaccines, tissues, and related data in support of both clinical and public health research; they store and distribute more than 170,000,000 samples in more than 20 facilities worldwide for government, academic, and pharmaceutical clients. Fisher BioServices is part of Thermo Fisher Scientific Inc., the world leader in serving science.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $13 billion, we have 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit http://www.thermofisher.com.

Read the full story at http://www.prweb.com/releases/FisherBioServices/CellTherapy/prweb11089099.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
2. Generex Secures Commitments for $3.6M Capital Raise
3. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
4. Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
5. Dr. Carlos Szajnert, Announced today his Commitment to Further Educate his Patients on the Benefits of Cord Blood Stem Cells
6. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
7. Vital Imaging Makes Greater Commitment into MRI Research
8. Gene Therapy - Technologies, Markets and Companies
9. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
10. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in ... 8:30aET on RFD-TV. , With global population estimates nearing ten billion people by ... feed a growing nation. At the same time, many of our valuable resources are ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments is ... Nanoscience Analytical offers a broad range of contract analysis services for advanced ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:6/23/2017)... and ITHACA, N.Y. , June ... Cornell University, a leader in dairy research, today announced ... designed to help reduce the chances that the global ... onset of this dairy project, Cornell University has become ... Sequencing the Food Supply Chain, a food safety initiative ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
Breaking Biology News(10 mins):